Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography

L. Tune; J. Brandt; J. J. Frost; G. Harris; H. Mayberg; C. Steele; A. Burns; J. Sapp; M. F. Folstein; H. N. Wagner; G. D. Pearlson

doi:10.1111/j.1600-0447.1991.tb03111.x

Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography

L. Tune, J. Brandt, J. J. Frost, G. Harris, H. Mayberg, C. Steele, A. Burns, J. Sapp, M. F. Folstein, H. N. Wagner, G. D. Pearlson

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

The effect of acute, intravenous administration of physostigmine on measures of brain activity and cognitive functioning were investigated in 14 patients with Alzheimer's disease. Regional cerebral glucose metabolism was assessed using (18F)‐fluoro‐2‐deoxy‐D‐glucose and positron emission tomography, and cerebral blood flow was assessed using ¹²³I‐iodoamphetamine single photon emission tomography. Although physostigmine enhanced cerebral blood flow in most patients, only one patient showed significant clinical improvement. This patient, however, also showed a very pronounced improvement in cerebral glucose metabolism. It is concluded that these preliminary findings hold considerable promise for our appreciation of the pathophysiology of dementing illness as well as our understanding of centrally acting compounds of interest in Alzheimer's disease.

Original language	English
Pages (from-to)	61-65
Number of pages	5
Journal	Acta Psychiatrica Scandinavica
Volume	83
Issue number	366 S
DOIs	https://doi.org/10.1111/j.1600-0447.1991.tb03111.x
State	Published - Sep 1991
Externally published	Yes

Keywords

Alzheimer's disease
cerebral blood flow
cerebral glucose metabolism
clinical improvement
physostigmine

Access to Document

10.1111/j.1600-0447.1991.tb03111.x

Fingerprint

Dive into the research topics of 'Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography'. Together they form a unique fingerprint.

Cite this

Tune, L., Brandt, J., Frost, J. J., Harris, G., Mayberg, H., Steele, C., Burns, A., Sapp, J., Folstein, M. F., Wagner, H. N., & Pearlson, G. D. (1991). Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatrica Scandinavica, 83(366 S), 61-65. https://doi.org/10.1111/j.1600-0447.1991.tb03111.x

@article{1112e613f6c845f99f440f67eaca92ec,

title = "Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography",

abstract = "The effect of acute, intravenous administration of physostigmine on measures of brain activity and cognitive functioning were investigated in 14 patients with Alzheimer's disease. Regional cerebral glucose metabolism was assessed using (18F)‐fluoro‐2‐deoxy‐D‐glucose and positron emission tomography, and cerebral blood flow was assessed using 123I‐iodoamphetamine single photon emission tomography. Although physostigmine enhanced cerebral blood flow in most patients, only one patient showed significant clinical improvement. This patient, however, also showed a very pronounced improvement in cerebral glucose metabolism. It is concluded that these preliminary findings hold considerable promise for our appreciation of the pathophysiology of dementing illness as well as our understanding of centrally acting compounds of interest in Alzheimer's disease.",

keywords = "Alzheimer's disease, cerebral blood flow, cerebral glucose metabolism, clinical improvement, physostigmine",

author = "L. Tune and J. Brandt and Frost, {J. J.} and G. Harris and H. Mayberg and C. Steele and A. Burns and J. Sapp and Folstein, {M. F.} and Wagner, {H. N.} and Pearlson, {G. D.}",

year = "1991",

month = sep,

doi = "10.1111/j.1600-0447.1991.tb03111.x",

language = "English",

volume = "83",

pages = "61--65",

journal = "Acta Psychiatrica Scandinavica",

issn = "0001-690X",

publisher = "John Wiley and Sons Inc.",

number = "366 S",

}

Tune, L, Brandt, J, Frost, JJ, Harris, G, Mayberg, H, Steele, C, Burns, A, Sapp, J, Folstein, MF, Wagner, HN & Pearlson, GD 1991, 'Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography', Acta Psychiatrica Scandinavica, vol. 83, no. 366 S, pp. 61-65. https://doi.org/10.1111/j.1600-0447.1991.tb03111.x

Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. / Tune, L.; Brandt, J.; Frost, J. J. et al.
In: Acta Psychiatrica Scandinavica, Vol. 83, No. 366 S, 09.1991, p. 61-65.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Physostigmine in Alzheimer's disease

T2 - effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography

AU - Tune, L.

AU - Brandt, J.

AU - Frost, J. J.

AU - Harris, G.

AU - Mayberg, H.

AU - Steele, C.

AU - Burns, A.

AU - Sapp, J.

AU - Folstein, M. F.

AU - Wagner, H. N.

AU - Pearlson, G. D.

PY - 1991/9

Y1 - 1991/9

N2 - The effect of acute, intravenous administration of physostigmine on measures of brain activity and cognitive functioning were investigated in 14 patients with Alzheimer's disease. Regional cerebral glucose metabolism was assessed using (18F)‐fluoro‐2‐deoxy‐D‐glucose and positron emission tomography, and cerebral blood flow was assessed using 123I‐iodoamphetamine single photon emission tomography. Although physostigmine enhanced cerebral blood flow in most patients, only one patient showed significant clinical improvement. This patient, however, also showed a very pronounced improvement in cerebral glucose metabolism. It is concluded that these preliminary findings hold considerable promise for our appreciation of the pathophysiology of dementing illness as well as our understanding of centrally acting compounds of interest in Alzheimer's disease.

AB - The effect of acute, intravenous administration of physostigmine on measures of brain activity and cognitive functioning were investigated in 14 patients with Alzheimer's disease. Regional cerebral glucose metabolism was assessed using (18F)‐fluoro‐2‐deoxy‐D‐glucose and positron emission tomography, and cerebral blood flow was assessed using 123I‐iodoamphetamine single photon emission tomography. Although physostigmine enhanced cerebral blood flow in most patients, only one patient showed significant clinical improvement. This patient, however, also showed a very pronounced improvement in cerebral glucose metabolism. It is concluded that these preliminary findings hold considerable promise for our appreciation of the pathophysiology of dementing illness as well as our understanding of centrally acting compounds of interest in Alzheimer's disease.

KW - Alzheimer's disease

KW - cerebral blood flow

KW - cerebral glucose metabolism

KW - clinical improvement

KW - physostigmine

UR - http://www.scopus.com/inward/record.url?scp=0025986127&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0447.1991.tb03111.x

DO - 10.1111/j.1600-0447.1991.tb03111.x

M3 - Article

C2 - 1897377

AN - SCOPUS:0025986127

SN - 0001-690X

VL - 83

SP - 61

EP - 65

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

IS - 366 S

ER -

Tune L, Brandt J, Frost JJ, Harris G, Mayberg H, Steele C et al. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatrica Scandinavica. 1991 Sep;83(366 S):61-65. doi: 10.1111/j.1600-0447.1991.tb03111.x